 ANDOVER, Mass., July 14, 2021 PRNewswire -- TransMedics Group, Inc. TransMedics Nasdaq: TMDX, a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of TransMedics clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration FDA has issued a favorable vote in support of approval of the OCS Liver System. 